Special Considerations in the Management of Women With HIV, Including Management of Conception and Pregnancy

  • Author: Kristine Patterson, MD (More Info)
  • Section Editor: Judith S. Currier, MD, MSc
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/5/18 (What's New)

Summary

  • IV zidovudine near delivery is recommended for HIV-infected pregnant women with HIV-1 RNA > 1000 copies/mL or unknown HIV-1 RNA levels unless there is evidence of resistance or toxicity (Management Guidelines)[DHHS Perinatal]
  • Neonatal zidovudine prophylaxis is also recommended for:[DHHS Perinatal]
    • 4 weeks for full-term infants whose mother received suppressive ART regimen during pregnancy
    • Mode of Delivery
      Concurrent Antiretroviral Therapy and Other Medications

      Action required

      Keywords: Drug-Drug Interactions, Pregnancy, Switch Strategies, Women

      ©2018 Clinical Care Options, LLC. All Rights Reserved.

      The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.